Product sheet

HEK293-CTLA4 | 305423

[redacted]

Description	[redacted]/[redacted] [redacted] [redacted] HEK293-CTLA4 [redacted] HEK293 [redacted] CTLA4 [redacted] [redacted] CTL [redacted] CTLA4 [redacted]
Organism	[redacted]
Tissue	[redacted]
Disease	[redacted]/[redacted]; [redacted] ([redacted] HEK293)
Applications	[redacted]; [redacted] CTLA4 (ipilimumab, [redacted] tremelimumab); [redacted]

[redacted]

Age	[redacted]
Gender	[redacted]
Morphology	[redacted]
Cell type	[redacted]
Growth properties	[redacted], [redacted]

[redacted]

Citation	HEK293-CTLA4 ([redacted] Cytion 305423)
Biosafety level	1
NCBI_TaxID	9606
CellosaurusAccession	CVCL_6G20

HEK293-CTLA4 | 305423

GMO Status	GMO-S1: HEK293 CTLA-4

Receptors expressed

Receptors expressed	4 (152)

Culture Medium

Culture Medium	RPMI 1640, w: 2.0 mM , w: 2.0 / NaHCO3 (Cytion 820700a)
Supplements	FBS 10%, 1 , HEPES 10 , NEAA 1%
Dissociation Reagent	-
Doubling time	24-36
Subculturing	: PBS
Split ratio	1 5
Seeding density	2 4 x /
Fluid renewal	2 3
Post-Thaw Recovery	1:2 1:3 T25
Freeze medium	(FBS) + 10% DMSO

HEK293-CTLA4 | 305423

Thawing and Culturing Cells	1. 2. cryovial -150 3. 37°C 4. 70% 5. 15 6. 300 x g 3 7. 10 8.
Incubation Atmosphere	37°C, 5% $_{CO2}$,
Flask Coating	
Freezing Procedure	
Shipping Conditions	
Storage Conditions	−150 −196 °C

Sterility	PCR